GlassScriptPhysician profile
Eric M Burns
NPI 1477597029
$2,555.98
in general payments reported to CMS, 2019-2025
20 companies · $581 in 2025
The $581 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $191 · 2021: $379 · 2022: $564 · 2023: $452 · 2024: $198 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $619.00 | 2021-2025 | Rocklatan, Rhopressa, Simbrinza |
| Notal Vision, INC. | $370.43 | 2022 | |
| Mallinckrodt Hospital Products INC. | $319.23 | 2021-2025 | Acthar |
| Biotissue Holdings INC. | $174.94 | 2020-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $158.42 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $129.82 | 2022-2025 | Vyzulta, Infuse, Miebo |
| Kala Pharmaceuticals, INC. | $123.42 | 2019 | |
| Allergan, INC. | $110.80 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $105.18 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $103.13 | 2019-2023 | Cequa |
| Ani Pharmaceuticals, INC. | $65.92 | 2023-2024 | Purified Cortrophin Gel |
| Lensar, INC. | $62.23 | 2025 | Lensar Laser System |
| Rxsight INC | $57.69 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $38.79 | 2020 | |
| Omeros Corporation | $36.34 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $21.96 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $19.12 | 2023 | Tyrvaya |
| Dentsply Sirona INC | $14.63 | 2023 | Suresmile |
| Aerie Pharmaceuticals, INC. | $12.71 | 2021 | |
| Shire North American Group INC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.